Mary K Floeter1, Bryan J Traynor2, Jennifer Farren2, Laura E Braun2, Michael Tierney2, Edythe A Wiggs2, Tianxia Wu2. 1. From the National Institute of Neurological Disorders and Stroke (M.K.F., J.F., L.E.B., M.T., E.A.W., T.W.) and National Institute of Aging (B.J.T.), NIH, Bethesda, MD. floeterm@ninds.nih.gov. 2. From the National Institute of Neurological Disorders and Stroke (M.K.F., J.F., L.E.B., M.T., E.A.W., T.W.) and National Institute of Aging (B.J.T.), NIH, Bethesda, MD.
Abstract
OBJECTIVE: To assess changes in 3 clinical measures, the Revised ALS Functional Rating Scale (ALSFRS-R), letter fluency, and Frontal Behavioral Inventory (FBI), over time in C9orf72 mutation carriers (C9+) with varied clinical phenotypes. METHODS: Thirty-four unrelated participants with mutations in C9orf72 were enrolled in a prospective natural history study. Participants were classified as asymptomatic, amyotrophic lateral sclerosis (ALS), ALS-familial frontotemporal dementia (FTD), or behavioral-variant FTD by clinical diagnostic criteria. Diagnostic cognitive and motor tests were repeated at 6 and 18 months. The ALSFRS-R, letter fluency, and FBI were administered at baseline and follow-up visits at 6, 12, and 18 months. RESULTS: The clinical diagnosis of most patients did not change over the follow-up. ALSFRS-R scores correlated with measures of motor function. Letter fluency correlated with FBI and cognitive tests. ALSFRS-R, letter fluency, and FBI differed among the C9+ diagnostic subgroups at enrollment and worsened over follow-up in symptomatic patients, with different slopes among the subgroups. Most patients survived to the 6-month time point after enrollment. Survival of C9+ patients with ALS and C9+ patients with ALS-FTD declined over the 12- and 18-month follow-up. CONCLUSIONS: The pattern of scores of the ALSFRS-R, letter fluency, and FBI distinguished between ALS, ALS-FTD, and FTD presentations of C9orf72 mutation carriers and asymptomatic carriers. Longitudinal changes in these measures occurred with disease progression in a manner consistent with presenting phenotype.
OBJECTIVE: To assess changes in 3 clinical measures, the Revised ALS Functional Rating Scale (ALSFRS-R), letter fluency, and Frontal Behavioral Inventory (FBI), over time in C9orf72 mutation carriers (C9+) with varied clinical phenotypes. METHODS: Thirty-four unrelated participants with mutations in C9orf72 were enrolled in a prospective natural history study. Participants were classified as asymptomatic, amyotrophic lateral sclerosis (ALS), ALS-familial frontotemporal dementia (FTD), or behavioral-variant FTD by clinical diagnostic criteria. Diagnostic cognitive and motor tests were repeated at 6 and 18 months. The ALSFRS-R, letter fluency, and FBI were administered at baseline and follow-up visits at 6, 12, and 18 months. RESULTS: The clinical diagnosis of most patients did not change over the follow-up. ALSFRS-R scores correlated with measures of motor function. Letter fluency correlated with FBI and cognitive tests. ALSFRS-R, letter fluency, and FBI differed among the C9+ diagnostic subgroups at enrollment and worsened over follow-up in symptomatic patients, with different slopes among the subgroups. Most patients survived to the 6-month time point after enrollment. Survival of C9+ patients with ALS and C9+ patients with ALS-FTD declined over the 12- and 18-month follow-up. CONCLUSIONS: The pattern of scores of the ALSFRS-R, letter fluency, and FBI distinguished between ALS, ALS-FTD, and FTD presentations of C9orf72 mutation carriers and asymptomatic carriers. Longitudinal changes in these measures occurred with disease progression in a manner consistent with presenting phenotype.
Authors: Katherine L Possin; Dana Feigenbaum; Katherine P Rankin; Glenn E Smith; Adam L Boxer; Kristie Wood; Sherrie M Hanna; Bruce L Miller; Joel H Kramer Journal: Neurology Date: 2013-05-08 Impact factor: 9.910
Authors: Emma Devenney; Michael Hornberger; Muireann Irish; Eneida Mioshi; James Burrell; Rachel Tan; Matthew C Kiernan; John R Hodges Journal: JAMA Neurol Date: 2014-03 Impact factor: 18.302
Authors: G Milan; F Lamenza; A Iavarone; F Galeone; E Lorè; C de Falco; P Sorrentino; A Postiglione Journal: Acta Neurol Scand Date: 2007-10-08 Impact factor: 3.209
Authors: Bradley F Boeve; Kevin B Boylan; Neill R Graff-Radford; Mariely DeJesus-Hernandez; David S Knopman; Otto Pedraza; Prashanthi Vemuri; David Jones; Val Lowe; Melissa E Murray; Dennis W Dickson; Keith A Josephs; Beth K Rush; Mary M Machulda; Julie A Fields; Tanis J Ferman; Matthew Baker; Nicola J Rutherford; Jennifer Adamson; Zbigniew K Wszolek; Anahita Adeli; Rodolfo Savica; Brendon Boot; Karen M Kuntz; Ralitza Gavrilova; Andrew Reeves; Jennifer Whitwell; Kejal Kantarci; Clifford R Jack; Joseph E Parisi; John A Lucas; Ronald C Petersen; Rosa Rademakers Journal: Brain Date: 2012-03 Impact factor: 13.501
Authors: Stacey Li Hi Shing; Mary Clare McKenna; We Fong Siah; Rangariroyashe H Chipika; Orla Hardiman; Peter Bede Journal: Brain Imaging Behav Date: 2021-01-05 Impact factor: 3.978
Authors: Alexander J Cammack; Nazem Atassi; Theodore Hyman; Leonard H van den Berg; Matthew Harms; Robert H Baloh; Robert H Brown; Michael A van Es; Jan H Veldink; Balint S de Vries; Jeffrey D Rothstein; Caroline Drain; Jennifer Jockel-Balsarotti; Amber Malcolm; Sonia Boodram; Amber Salter; Nicholas Wightman; Hong Yu; Alexander V Sherman; Thomas J Esparza; Diane McKenna-Yasek; Margaret A Owegi; Catherine Douthwright; Alexander McCampbell; Toby Ferguson; Carlos Cruchaga; Merit Cudkowicz; Timothy M Miller Journal: Neurology Date: 2019-10-02 Impact factor: 9.910
Authors: Elena Ratti; Kimiko Domoto-Reilly; Christina Caso; Alyssa Murphy; Michael Brickhouse; Daisy Hochberg; Nikos Makris; Merit E Cudkowicz; Bradford C Dickerson Journal: Brain Imaging Behav Date: 2021-02-15 Impact factor: 3.224
Authors: Hans-Peter Müller; Dorothée Lulé; Francesco Roselli; Anna Behler; Albert C Ludolph; Jan Kassubek Journal: Ther Adv Chronic Dis Date: 2021-03-21 Impact factor: 5.091
Authors: Jackie M Poos; Katrina M Moore; Jennifer Nicholas; Lucy L Russell; Georgia Peakman; Rhian S Convery; Lize C Jiskoot; Emma van der Ende; Esther van den Berg; Janne M Papma; Harro Seelaar; Yolande A L Pijnenburg; Fermin Moreno; Raquel Sanchez-Valle; Barbara Borroni; Robert Laforce; Mario Masellis; Carmela Tartaglia; Caroline Graff; Daniela Galimberti; James B Rowe; Elizabeth Finger; Matthis Synofzik; Rik Vandenberghe; Alexandre de Mendonça; Pietro Tiraboschi; Isabel Santana; Simon Ducharme; Chris Butler; Alexander Gerhard; Johannes Levin; Adrian Danek; Markus Otto; Isabel Le Ber; Florence Pasquier; John C van Swieten; Jonathan D Rohrer Journal: Alzheimers Res Ther Date: 2022-01-19 Impact factor: 6.982